Key facts
- This page summarizes Michael J. Brown's Form 4 filing for Monopar Therapeutics (MNPR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jan 2024, 19:40.
Michael J. Brown - 31 Dec 2023 Form 4 Insider Report for Monopar Therapeutics (MNPR)
- Reporting relationship
- Director
- Issuer ticker
- MNPR
- Reported as of
- 31 Dec 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2024, 19:40:23 UTC
- Prior SEC filing
- 14 Dec 2023
- Next SEC filing
- 26 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kim R. Tsuchimoto, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael J. Brown filed Form 4 for Monopar Therapeutics (MNPR) on 03 Jan 2024.
Change
- Previous filing in this sequence was filed on 14 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MNPR
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,533
- Change %
- +1.1%
- Price
- Shares after
- 235,863
- Date
- 31 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
MNPR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,111,273
- Date
- 31 Dec 2023
- Ownership
- See Footnote
- Footnotes
- F2
MNPR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 166,667
- Date
- 31 Dec 2023
- Ownership
- See Footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MNPR
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,533
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 31 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,533
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares acquired on vesting and settlement of restricted stock units.
Footnote F2
This is based upon the 4,111,272.88 shares of Monopar common stock that Tactic Pharma LLC indirectly controls through TacticGem LLC. As a manager of Tactic Pharma LLC, Mr. Brown may be deemed to share voting and dispositive power over these 4,111,272.88 shares. Mr. Brown disclaims beneficial ownership of the 4,111,272.88 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
Footnote F3
This is based upon the 166,667 shares of Monopar common stock that Tactic Pharma LLC directly owns. As a manager of Tactic Pharma LLC, Mr. Brown may be deemed to share voting and dispositive power over these 166,667 shares. Mr. Brown disclaims beneficial ownership of the 166,667 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
Footnote F4
On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.